SiRan Bio

SiRan Bio (时安生物) is a Suzhou-based biotech company focused on innovative siRNA drug development, founded in 2022 in Suzhou Industrial Park . The company has built a proprietary nucleic acid drug technology platform centered on two differentiated directions: single-molecule dual-target siRNA and extrahepatic delivery . Its STORK-F fat-targeting delivery platform produced SA030, an ALK7 siRNA candidate that became one of the first three globally to reach clinical development for this target and attracted a global exclusive licensing agreement with GSK (excluding Greater China) in May 2026, with potential milestone payments up to $1.005 billion . The company also advanced SA1211, the world's first single-molecule dual-target siRNA candidate to enter clinical trials, targeting functional cure of chronic hepatitis B . BlueRun Ventures led SiRan Bio's Pre-A round in 2024 and made additional investments through 2025, including an oversubscribed Series A totaling nearly RMB 400 million announced in August 2026 . The founding team includes scientists from Peking University, Tsinghua, Harvard, Columbia, and the University of Freiburg, with over two decades of nucleic acid drug R&D experience; founder Dr. Yang Zhiwei was a core inventor of the Lipofectamine™ transfection reagent series .